Bone sialoprotein(BSP)is an important non-collagen extracellular matrix protein(EMC)that promotes bone formation and induces bone resorption.BSP is secreted by odontoblasts,it plays an important role in cementum,alveo...Bone sialoprotein(BSP)is an important non-collagen extracellular matrix protein(EMC)that promotes bone formation and induces bone resorption.BSP is secreted by odontoblasts,it plays an important role in cementum,alveolar bone formation and mineralization,and periodontal function.Bone resorption is controlled by a complex molecular network,and BSP can promote osteoclast differentiation and bone resorption.It is also associated with the metastasis of a range of malignancies.Osteoclasts(OC)are thought to be the only cells involved in bone resorption and play an important role in bone formation and late developmental remodeling.Osteoporosis and periodontal disease are caused by excessive bone resorption.This article will summarize the osteoclasts differentiation,the biological function of bone resorption,and explore the progress of the prevention and treatment of the related bone resorption diseases such as osteoporosis and periodontal disease through the regulation of osteoclasts.展开更多
Summary： This study aimed to evaluate the diagnostic and prognostic significance of serum bone sialoprotein （BSP） and prostate-specific antigen doubling time （PSADT） in patients with bone metastasis （BM） from p...Summary： This study aimed to evaluate the diagnostic and prognostic significance of serum bone sialoprotein （BSP） and prostate-specific antigen doubling time （PSADT） in patients with bone metastasis （BM） from prostate cancer （PC）. A total of 116 patients with PC, 120 patients with benign prostatic hyperplasia （BPH） and 120 healthy controls were enrolled in this study. PC patients were divided into bone metastasis （BM） group （n=56） and non-bone metastasis （NBM） group （n=60）. Serum BSP was detected by Sandwich ELISA. Severity of bone pain was evaluated using visual analogue score （VAS）. Serum f-PSA and t-PSA levels were measured by using electrochemiluminescence immunoassay （ECLIA）. PSADT was calculated according to the formula： PSADT=lg（2）/[log（PSA2）--log（PSA1）]. The mean serum BSP level in PC patients with BM was significantly higher than in PC patients without BM, BPH patients and controls （P〈0.001 for all）. Pearson＇s analysis showed that serum BSP level was posi- tively correlated with VAS in PC patients with BM （P〈0.05）. Receiver operating characteristics （ROC） analysis demonstrated that BSP discriminated patients with BM from those without BM at the cutoff value of 33.26 ng/mL. The sensitivity and specificity were 78.21% and 79.28%, respectively. The opti- mal cutoff value of PSADT was 131 days, with sensitivity of 85.69% and specificity of 85.36%. Kap- lan-Meier analysis revealed that subjects with higher BSP levels/shorter PSADT had a shorter BM-free period than those with lower BSP levels/longer PSADT. Serum BSP and PSADT are useful biomarkers for the diagnosis of BM from PC, and can be regarded as independent factors for predicting the progno- sis of BM from PC. Combined determination of BSP and PSADT can improve accuracy and positive rate of BM from PC significantly.展开更多
Objective With the unique properties of Au nano-particles,a nano-piezoelectric immunosensor microarray was designed using AT-cut 10 Hz quartz crystal to detect blood sialoprotein (BSP) expression from clinical serum.M...Objective With the unique properties of Au nano-particles,a nano-piezoelectric immunosensor microarray was designed using AT-cut 10 Hz quartz crystal to detect blood sialoprotein (BSP) expression from clinical serum.Methods展开更多
目的研究恶性肿瘤患者骨转移及其他脏器转移时血清骨唾液酸蛋白(bone sialoprotein,BSP)、I型胶原氨基末端肽(N-terminal telopeptide of type I collagen,NTx)的水平变化。方法收集天津市第四中心医院肿瘤血液科2013年9月至2014年9月...目的研究恶性肿瘤患者骨转移及其他脏器转移时血清骨唾液酸蛋白(bone sialoprotein,BSP)、I型胶原氨基末端肽(N-terminal telopeptide of type I collagen,NTx)的水平变化。方法收集天津市第四中心医院肿瘤血液科2013年9月至2014年9月间收治的资料完整的恶性肿瘤患者49例,其中无转移组(CO组)17例,其他脏器转移组(CM组)15例,骨转移组(CB组)17例,酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)试剂盒检测BSP、NTx血清水平。结果1)CB组BSP水平明显高于CO及CM组[分别为(4305.45±964.83)pg/mL、(3302.50±748.67)pg/mL、(3326.34±920.94)pg/mL],且组间差异有统计学意义(P值分别为0.002、0.007)。2)CB组NTx水平明显高于CO及CM组[分别为(58.66±14.33)ng/mL、(39.24±12.62)ng/mL、(47.71±15.49)ng/mL],且组间差异有统计学意义(P值分别为<0.001、0.047)。3)CO与CM组之间BSP及NTx水平近似,组间差异无统计学意义(P值分别为0.963、0.099)。结论血清BSP及NTX水平测定可以作为临床早期监测恶性肿瘤骨转移的特异性指标,试验方法简单,操作方便,有利于临床上广泛开展。展开更多
目的:探讨骨代谢生化指标血清Ⅰ型胶原交联氨基末端肽(N-telopeptide of typeⅠcollagen,NTx)和骨涎酸蛋白(bone sialoprotein,BSP)的检测对肺癌和乳腺癌骨转移的临床意义。方法:选择2006年1月至2006年7月长海医院肿瘤科经病理确诊的肺...目的:探讨骨代谢生化指标血清Ⅰ型胶原交联氨基末端肽(N-telopeptide of typeⅠcollagen,NTx)和骨涎酸蛋白(bone sialoprotein,BSP)的检测对肺癌和乳腺癌骨转移的临床意义。方法:选择2006年1月至2006年7月长海医院肿瘤科经病理确诊的肺癌或乳腺癌患者105例,分为两组,其中骨转移组50例,无骨转移组55例。应用ELISA法检测患者血清NTx和BSP浓度。结果:骨转移组患者血清NTx和BSP水平均明显高于无骨转移组(P<0.01)。NTx诊断骨转移的灵敏度和特异度分别为90.0%和67.3%,BSP诊断骨转移的灵敏度和特异度分别为84.0%和70.9%。临床发生骨相关事件(skeletal related event,SRE)的骨转移患者,血清NTx水平明显高于未发生SRE的骨转移患者(P<0.05)。在6～13个月随访期内,21例患者确诊了新发骨转移;采用Cox比例风险回归模型分析,血清NTx浓度升高提示骨转移发生的相对危险度为1.127;乳腺癌患者血清BSP增高是唯一预测骨转移的危险因素(P<0.05),其相对危险度为1.058。随访期共有33例患者死亡;无论肺癌还是乳腺癌,血清BSP增高患者的累积生存率均明显低于血清BSP正常组(P<0.05)。结论:血清NTx和BSP是诊断肺癌和乳腺癌骨转移的重要参考指标,其水平的增高是预测骨转移发生的高危因素;BSP可能是肺癌和乳腺癌患者独立预后指标。展开更多
基金National Natural Science Foundation Project(No.81260275)。
文摘Bone sialoprotein(BSP)is an important non-collagen extracellular matrix protein(EMC)that promotes bone formation and induces bone resorption.BSP is secreted by odontoblasts,it plays an important role in cementum,alveolar bone formation and mineralization,and periodontal function.Bone resorption is controlled by a complex molecular network,and BSP can promote osteoclast differentiation and bone resorption.It is also associated with the metastasis of a range of malignancies.Osteoclasts(OC)are thought to be the only cells involved in bone resorption and play an important role in bone formation and late developmental remodeling.Osteoporosis and periodontal disease are caused by excessive bone resorption.This article will summarize the osteoclasts differentiation,the biological function of bone resorption,and explore the progress of the prevention and treatment of the related bone resorption diseases such as osteoporosis and periodontal disease through the regulation of osteoclasts.
基金supported by a grant from the Scientific and Technological Department of Hunan Province in 2005(No.05FJ3033)
文摘Summary： This study aimed to evaluate the diagnostic and prognostic significance of serum bone sialoprotein （BSP） and prostate-specific antigen doubling time （PSADT） in patients with bone metastasis （BM） from prostate cancer （PC）. A total of 116 patients with PC, 120 patients with benign prostatic hyperplasia （BPH） and 120 healthy controls were enrolled in this study. PC patients were divided into bone metastasis （BM） group （n=56） and non-bone metastasis （NBM） group （n=60）. Serum BSP was detected by Sandwich ELISA. Severity of bone pain was evaluated using visual analogue score （VAS）. Serum f-PSA and t-PSA levels were measured by using electrochemiluminescence immunoassay （ECLIA）. PSADT was calculated according to the formula： PSADT=lg（2）/[log（PSA2）--log（PSA1）]. The mean serum BSP level in PC patients with BM was significantly higher than in PC patients without BM, BPH patients and controls （P〈0.001 for all）. Pearson＇s analysis showed that serum BSP level was posi- tively correlated with VAS in PC patients with BM （P〈0.05）. Receiver operating characteristics （ROC） analysis demonstrated that BSP discriminated patients with BM from those without BM at the cutoff value of 33.26 ng/mL. The sensitivity and specificity were 78.21% and 79.28%, respectively. The opti- mal cutoff value of PSADT was 131 days, with sensitivity of 85.69% and specificity of 85.36%. Kap- lan-Meier analysis revealed that subjects with higher BSP levels/shorter PSADT had a shorter BM-free period than those with lower BSP levels/longer PSADT. Serum BSP and PSADT are useful biomarkers for the diagnosis of BM from PC, and can be regarded as independent factors for predicting the progno- sis of BM from PC. Combined determination of BSP and PSADT can improve accuracy and positive rate of BM from PC significantly.
文摘Objective With the unique properties of Au nano-particles,a nano-piezoelectric immunosensor microarray was designed using AT-cut 10 Hz quartz crystal to detect blood sialoprotein (BSP) expression from clinical serum.Methods
文摘目的研究恶性肿瘤患者骨转移及其他脏器转移时血清骨唾液酸蛋白(bone sialoprotein,BSP)、I型胶原氨基末端肽(N-terminal telopeptide of type I collagen,NTx)的水平变化。方法收集天津市第四中心医院肿瘤血液科2013年9月至2014年9月间收治的资料完整的恶性肿瘤患者49例,其中无转移组(CO组)17例,其他脏器转移组(CM组)15例,骨转移组(CB组)17例,酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)试剂盒检测BSP、NTx血清水平。结果1)CB组BSP水平明显高于CO及CM组[分别为(4305.45±964.83)pg/mL、(3302.50±748.67)pg/mL、(3326.34±920.94)pg/mL],且组间差异有统计学意义(P值分别为0.002、0.007)。2)CB组NTx水平明显高于CO及CM组[分别为(58.66±14.33)ng/mL、(39.24±12.62)ng/mL、(47.71±15.49)ng/mL],且组间差异有统计学意义(P值分别为<0.001、0.047)。3)CO与CM组之间BSP及NTx水平近似,组间差异无统计学意义(P值分别为0.963、0.099)。结论血清BSP及NTX水平测定可以作为临床早期监测恶性肿瘤骨转移的特异性指标,试验方法简单,操作方便,有利于临床上广泛开展。
文摘目的:探讨骨代谢生化指标血清Ⅰ型胶原交联氨基末端肽(N-telopeptide of typeⅠcollagen,NTx)和骨涎酸蛋白(bone sialoprotein,BSP)的检测对肺癌和乳腺癌骨转移的临床意义。方法:选择2006年1月至2006年7月长海医院肿瘤科经病理确诊的肺癌或乳腺癌患者105例,分为两组,其中骨转移组50例,无骨转移组55例。应用ELISA法检测患者血清NTx和BSP浓度。结果:骨转移组患者血清NTx和BSP水平均明显高于无骨转移组(P<0.01)。NTx诊断骨转移的灵敏度和特异度分别为90.0%和67.3%,BSP诊断骨转移的灵敏度和特异度分别为84.0%和70.9%。临床发生骨相关事件(skeletal related event,SRE)的骨转移患者,血清NTx水平明显高于未发生SRE的骨转移患者(P<0.05)。在6～13个月随访期内,21例患者确诊了新发骨转移;采用Cox比例风险回归模型分析,血清NTx浓度升高提示骨转移发生的相对危险度为1.127;乳腺癌患者血清BSP增高是唯一预测骨转移的危险因素(P<0.05),其相对危险度为1.058。随访期共有33例患者死亡;无论肺癌还是乳腺癌,血清BSP增高患者的累积生存率均明显低于血清BSP正常组(P<0.05)。结论:血清NTx和BSP是诊断肺癌和乳腺癌骨转移的重要参考指标,其水平的增高是预测骨转移发生的高危因素;BSP可能是肺癌和乳腺癌患者独立预后指标。
